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Genome-wide association studies have implicated PLEXIN D1
(PLXND1) in body fat distribution and type 2 diabetes. However,
a role for PLXND1 in regional adiposity and insulin resistance is
unknown. Here we use in vivo imaging and genetic analysis in
zebrafish to show that Plxnd1 regulates body fat distribution
and insulin sensitivity. Plxnd1 deficiency in zebrafish induced hy-
perplastic morphology in visceral adipose tissue (VAT) and reduced
lipid storage. In contrast, subcutaneous adipose tissue (SAT)
growth and morphology were unaffected, resulting in altered
body fat distribution and a reduced VAT:SAT ratio in zebrafish. A
VAT-specific role for Plxnd1 appeared conserved in humans, as
PLXND1 mRNA was positively associated with hypertrophic mor-
phology in VAT, but not SAT. In zebrafish plxnd1mutants, the effect
on VAT morphology and body fat distribution was dependent on
induction of the extracellular matrix protein collagen type V alpha 1
(col5a1). Furthermore, after high-fat feeding, zebrafish plxnd1 mu-
tant VAT was resistant to expansion, and excess lipid was dispro-
portionately deposited in SAT, leading to an even greater
exacerbation of altered body fat distribution. Plxnd1-deficient
zebrafish were protected from high-fat-diet-induced insulin re-
sistance, and human VAT PLXND1 mRNA was positively associated
with type 2 diabetes, suggesting a conserved role for PLXND1 in
insulin sensitivity. Together, our findings identify Plxnd1 as a novel
regulator of VAT growth, body fat distribution, and insulin sensi-
tivity in both zebrafish and humans.
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The regional distribution and morphology of adipose tissue(AT) are strong predictors of metabolic disease (1–3). Excess
lipid deposition in visceral AT (VAT; adipose associated with
visceral organs) is associated with increased susceptibility to in-
sulin resistance and type 2 diabetes (4), whereas expansion of
subcutaneous AT (SAT; adipose between muscle and skin) is
associated with reduced risk for metabolic disease and is even
protective against hyperglycemia and dyslipidemia (4–7). In turn,
hypertrophic AT morphology (few large adipocytes) is associated
with insulin resistance and AT dysfunction, whereas hyperplastic
AT morphology (many small adipocytes) is associated with im-
proved metabolic parameters (4, 7–9). Therefore, the identification
of factors that regulate regional distribution and AT morphology
could lead to new therapies to treat metabolic disease.
Genome-wide association studies have implicated the PLEXIN
D1 (PLXND1) locus in waist:hip ratio (a measurement of regional
AT distribution) and type 2 diabetes (10). However, a role for
Plxnd1 in AT morphology, distribution, and metabolism is un-
known. Plxnd1 is a transmembrane receptor that controls the
migration, proliferation, and survival of diverse cell types (11).
Mutation of Plxnd1 in mouse and zebrafish leads to hyper-
vascularization in many tissues (12, 13), and vascular endothelial
cell Plxnd1 modulates extracellular matrix (ECM) synthesis and
composition by regulating the collagen receptor, β1-integrin (14). In
turn, ECM provides a supportive microenvironment for AT growth
and function (15). For example, type V collagens regulate collagen
fiber assembly, geometry, and strength (16, 17), are up-regulated
during adipogenesis, and can stimulate adipocyte differentiation in
vitro (18–20). However, the role of type V collagens during in vivo
AT growth is unknown.
In this study, we use genetic analysis and in vivo imaging of lipid
deposition dynamics in zebrafish to assess the role of Plxnd1 in AT
morphology and body fat distribution. Previous studies have shown
that zebrafish adipocytes and AT are morphologically, molecularly,
and functionally homologous to mammalian white AT (21–26), and
like mammals, zebrafish adipocytes accumulate a large cytoplasmic
lipid droplet (LD) that facilitates the in vivo identification of adi-
pocytes by fluorescent lipophilic dyes (21, 22, 24–26). Here we
determine in zebrafish that Plxnd1 functions through Col5a1 to
exert a VAT-specific effect on adipose growth and morphology,
resulting in altered body fat distribution and improved insulin
sensitivity. In accord, molecular and physiological assessments in
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humans support a conserved role for PLXND1 in regulation of
VAT morphology and insulin sensitivity.
Results
Zebrafish plxnd1 Mutants Have Reduced Lipid Accumulation in VAT
and Altered Body Fat Distribution. To test the role of Plxnd1 in body
fat distribution, we first analyzed lipid deposition in homozygous
Plxnd1 knockout mice; however, these mice die at birth before
extensive formation of VAT (SI Appendix, Fig. S1). Therefore, we
turned to the zebrafish model system. Homozygous plxnd1 null
zebrafish mutants and their phenotypically normal siblings were
stained with the neutral lipid dye Nile Red, and individual ATs were
categorized into VAT, SAT or miscellaneous AT (cranial or asso-
ciated with the skeleton) (Fig. 1A and SI Appendix, Fig. S2A). We
then measured AT area, which has been previously shown to ac-
curately predict triacylglyceride content (24). Total AT area per
fish was indistinguishable between plxnd1 mutants and siblings
(Fig. 1 A and B and SI Appendix, Fig. S2B), and total extracted
lipid levels per fish were identical (SI Appendix, Fig. S2C). How-
ever, VAT area and volume were significantly decreased in plxnd1
mutants (Fig. 1 A and B and SI Appendix, Fig. S2D). In contrast,
no significant change was observed between plxnd1 mutants and
siblings in SAT or miscellaneous AT-localized lipid storage (Fig.
1B and SI Appendix, Fig. S2D), suggesting Plxnd1 exerts a VAT-
specific effect. The decrease in VAT area in plxnd1 mutants led to
a reduced VAT:SAT ratio (Fig. 1B). Thus, mutation of plxnd1 in
zebrafish is associated with reduced lipid storage in VAT and
altered body fat distribution.
Plxnd1 Deficiency Induces a Hyperproliferative and Hyperplastic State
in Zebrafish VAT. We next quantified LD number and size as
measures of hyperplastic and hypertrophic AT morphology (25).
Both sibling and plxnd1 mutant VAT had a bimodal distribution
of LD sizes containing a population of very small LDs that was
unaltered between genotypes (Fig. 1 C and D), as well as a sec-
ond population of large LDs that was significantly smaller in
plxnd1 mutants compared with in siblings (Fig. 1 C and D and SI
Appendix, Fig. S3A). Volumetric measurements supported the
smaller size of plxnd1 mutant VAT LDs (SI Appendix, Fig. S3 B
and C). Furthermore, plxnd1 mutants had a greater number of
LDs per unit volume (Fig. 1C and SI Appendix, Fig. S3D), and
histology confirmed the hyperplastic morphology of plxnd1 mu-
tant VAT (SI Appendix, Fig. S3 E–G). plxnd1 mutant VAT had
a greater number of 5-ethynyl-2-deoxyuridine–labeled (EdU+)
proliferating cells than sibling VAT (Fig. 1 C and E), of which
the majority of EdU+ nuclei belonged to either adipocytes or
endothelial cells (Fig. 1F and SI Appendix, Fig. S4). Further,
quantitative RT-PCR (qRT-PCR) revealed an increased ex-
pression of adipocyte differentiation genes (Fig. 1G). In contrast,
the morphology of plxnd1 SAT was indistinguishable from that of
siblings (SI Appendix, Fig. S5). Together, these data demonstrate
that Plxnd1 deficiency induces adipocyte hyperproliferation, in-
duction of adipocyte differentiation genes, and hyperplastic VAT
morphology without affecting SAT morphology.
PLXND1mRNA Is Positively Associated with Hypertrophic Morphology
in Human VAT, but not SAT. As Plxnd1 deficiency in zebrafish led to
VAT-specific changes in morphology and altered body fat distri-
bution, we next investigated whether a similar relationship existed
in humans. Multiple regression analysis (adjusting for age and body
mass index) revealed a positive association between VAT PLXND1
mRNA and more pronounced hypertrophic morphology in VAT
(R2 = 0.22 and P = 0.031) (Fig. 1H), although no correlation was
observed between PLXND1 mRNA and morphology in SAT (SI
Appendix, Fig. S2E). Thus, these data demonstrate that PLXND1
mRNA exhibits a VAT-specific association with morphology in
humans, wherein greater levels of PLXND1 mRNA are associated
with VAT hypertrophy and lower levels of PLXND1 mRNA are
associated with hyperplastic VAT morphology. These data, to-
gether with the zebrafish data, suggest a conserved role for Plxnd1
in promoting hypertrophic VAT morphology.
Col5a1 Is Induced by Vascular Endothelial Cells of plxnd1 Mutant VAT.
Because Plxnd1 is known to modulate ECM synthesis and
composition (14, 27), we next analyzed ECM dynamics in plxnd1
mutant zebrafish. qRT-PCR revealed large-scale dysregulation
of ECM components within plxnd1 mutant VAT (Fig. 2A). In
general, ECM components were down-regulated (Fig. 2A);
Fig. 1. Reduced VAT volume and hyperplastic morphology underlie an al-
tered body fat distribution in plxnd1 mutant zebrafish. (A) Fluorescent ste-
reoscope images of Nile Red-stained zebrafish inverted and false colored
according to VAT (magenta), SAT (yellow), or miscellaneous AT (blue). Fish
were 10.1 mm standard length. (B) VAT area is reduced in plxnd1 zebrafish
(P = 0.0115), leading to a decreased VAT:SAT ratio (inset, P < 0.0001). There
were trends toward increases in SAT (P = 0.142), miscellaneous AT (P =
0.053), and total adiposity (P = 0.085) that did not reach statistical signifi-
cance (α = 0.05). (C) Maximum-intensity projections of zebrafish VAT stained
with LipidTOX (LDs, green), Hoechst (nuclei, blue), and EdU (proliferative
nuclei, magenta). Arrows indicate EdU+ nuclei. (D) Probability density
functions to represent VAT-LD diameter distributions. VAT-LD diameters
were modeled using a mixture of two normal distributions. The mean (μ) of
each distribution is indicated (μ1 and μ2). (E) Quantification of EdU+ nuclei
normalized to total nuclei from Z-stacks. (F) Colocalization of EdU+ nuclei
(magenta) with LD-containing adipocytes (Adipo.), as identified using the
plasma membrane dye CellMask (green) and LipidTOX (blue); AT macro-
phages (ATMs), as identified by WCL15 antibody reactivity (green); and
endothelial cells (ECs), as identified by EGFP (green), from the fli1a:EGFP
transgenic line. Quantification of EdU+ nuclei in these cell types revealed
a significant increase in endothelial cells and adipocytes in plxnd1 mutants.
(G) The mRNA levels for adipocyte differentiation markers cebpa, cebpb, and
pparg were increased in plxnd1 VAT by qRT-PCR. Fabp11a, a homolog of
mammalian Fabp4/aP2, was unchanged. (H) A significant positive correlation
was observed between VAT PLXND1 mRNA and hypertrophic VAT morphol-
ogy in humans. No correlation was observed in human SAT (SI Appendix, Fig.
S2E). Fish were ∼12 mm standard length unless otherwise stated.
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however, the type V collagens col5a1 and col5a3b were increased
(Fig. 2A). Intriguingly, type V collagens have been previously
shown to induce proliferation and differentiation of preadipocytes
in vitro (19, 20) and regulate collagen fibrillogenesis to control
ECM geometry and tensile strength (16, 17), properties that have
been implicated in metabolic dysfunction of obese AT (28). Im-
munofluorescence confirmed an increase in Col5 protein and
revealed specific localization to vascular endothelial cells in plxnd1
mutant VAT (Fig. 2 B–D and SI Appendix, Fig. S6), a site previously
associated with COL5A1 protein localization in human AT (18).
FACS enrichment of endothelial cells followed by qRT-PCR de-
termined that col5a1 mRNA was increased in plxnd1 mutant en-
dothelial cells (Fig. 2E), supporting a vascular endothelial cell origin
for Col5a1 in plxnd1 mutant VAT.
Knockdown of Col5a1 Normalizes Hyperproliferation and Hyper-
plastic Morphology Within plxnd1 Mutant VAT. We hypothesized
that induction of Col5a1 in plxnd1 mutant VAT establishes
a microenvironment conducive to hyperplastic growth. To test
this, we targeted zebrafish col5a1 with multiple, nonoverlapping
vivo-morpholinos (vMOs). Serial injection of either vMO disrupted
splicing of col5a1, and RT-PCR followed by sequencing confirmed
the production of truncated col5a1 mRNAs predicted to be non-
functional (col5a1-i1e2, 55 amino acids; col5a1-e3i3, 112 amino
acids) (SI Appendix, Fig. S7 C and D). Assessment of Col5 reactivity
after injection of col5a1-i1e2 vMO revealed significantly reduced
Col5 protein levels in both endothelial cell and periadipocyte
locations (SI Appendix, Fig. S8). Injection of either col5a1 vMO did
not affect proliferation or morphology of sibling VAT (Fig. 2 F–H).
However, in hyperplastic plxnd1 mutant VAT, injection of col5a1
vMO increased LD hypertrophy and induced the appearance of an
additional population of very large LDs (μ3 = 122.59 μm; Fig. 2 F
and G). Further, col5a1 vMO normalized levels of EdU+ nuclei in
plxnd1 mutant VAT (Fig. 2 F and H), and volumetric analysis
revealed a partial rescue of lipid storage in plxnd1 mutant VAT
(Fig. 2I), thus increasing the VAT:SAT ratio (Fig. 2J). Therefore,
Col5a1 is required for maintenance of the hyperplastic state of
plxnd1 mutant VAT and the resulting body fat distribution.
plxnd1Mutant VAT Undergoes Augmented Fibrillogenesis in a Col5a1-
Dependent Manner. Our data suggest that zebrafish Plxnd1
modulates body fat distribution by determining the status of the
VAT ECM microenvironment. To ascertain the architectural
properties of ECM, we used the fluorescent collagen probe
5-(4,6-dichlorotriazinyl) aminofluorescein to label VAT-localized
collagen fibers (SI Appendix, Fig. S9A) (28). ECM architecture of
plxnd1 mutant VAT was markedly different from that of sibling
VAT (Fig. 3A) and was characterized by larger and more nu-
merous interstitial collagen fibers (Figs. 3A and SI Appendix, Fig.
S10). Moreover, plxnd1 mutant VAT had increased glycoprotein,
elastin content (SI Appendix, Fig. S11), and a greater abundance
of fibrous ECM (SI Appendix, Fig. S11). plxnd1 mutant SAT did
not have altered collagen or fibrous ECM (SI Appendix, Fig. S11
H and I), again demonstrating the starkly different response of
VAT and SAT to Plxnd1 deficiency. To assess fibrillogenesis in
plxnd1mutant VAT, we extracted ECM from zebrafish VAT and
induced polymerization and gel formation in vitro (SI Appendix,
Fig. S12). We then conducted turbidity assays to determine the
rate and ultimate extent of fibrillogenesis. Plxnd1-deficient VAT
underwent an increased rate of fibrillogenesis compared with
sibling ECM (Fig. 3B), and plxnd1 mutant VAT attained a higher
ultimate turbidity than sibling VAT (Fig. 3C). Injection of col5a1-
i1e2 vMO did not affect in vitro fibrillogenesis of sibling VAT;
however, col5a1 vMO injection significantly reduced both the rate
of fibrillogenesis and ultimate turbidity in plxnd1 mutant VAT
(Fig. 3 B and C). Therefore, ECM from plxnd1 mutant VAT has
markedly different properties than wild-type VAT and undergoes
augmented fibrillogenesis in a Col5a1-dependent manner.
plxnd1 Mutant ECM Is Sufficient to Induce Hyperproliferation and
Hyperplastic Morphology of Stromal Vascular Cells In Vitro. We
next wished to test whether ECM of Plxnd1-deficient VAT is
sufficient to instruct VAT cell proliferation and morphology.
Isolated ECM from zebrafish VAT was used as a substrate for
the culture of primary stromal vascular cells (SVCs) also isolated
from zebrafish VAT (Fig. 3D). When cultured within a 3D ECM
substrate obtained from sibling VAT, sibling SVCs were able to
proliferate and readily differentiate into adipocytes containing
large LDs (Fig. 3 E and G). In contrast, plxnd1 mutant SVCs
cultured on ECM derived from plxnd1 mutant ECM reached
a higher level of confluency (Fig. 3 E and F and SI Appendix, Fig.
S13A), together with strikingly smaller LDs (Fig. 3 E and G and
SI Appendix, Fig. S13A). The degree of confluency and LD hy-
pertrophy were ECM extract-dependent, as culturing sibling
SVCs within ECM from plxnd1 mutants increased confluency
and reduced LD size (Fig. 3 E–G). Conversely, culturing plxnd1
Fig. 2. Col5a1 is essential for maintenance of the hyperproliferative and hy-
perplastic state of plxnd1mutant VAT. (A) qRT-PCR for ECMmarkers from whole
zebrafish VAT reveals an up-regulation of col5a1 in plxnd1 VAT. All mRNAs
shown were significantly different between plxnd1 and siblings (α = 0.05).
(B) Immunofluorescence for type V collagens (Col5) (Left, magenta; Right, white)
reveals increased Col5 accumulation in association with endothelial cells in
plxnd1 VAT (arrows). Asterisks indicate nonendothelial peri-adipocyte localized
Col5. (C) Quantification of Col5 area. Area is expressed as percentage of field of
view. (D) Quantification of Col5 signal in endothelial cells relative to background.
(E) qRT-PCR on adipocyte (Adipo.) and SVC fractions reveals col5a1 is enriched in
SVCs of plxnd1 VAT. FACS enrichment of EGFP+ endothelial cells from fli1a:EGFP
plxnd1 mutant and sibling VAT show that SVC-derived col5a1 is up-regulated in
plxnd1 endothelial cells. (F) Maximum-intensity projections of VAT from sibling
or plxnd1 animals injected with either control or col5a1 vMO. Images are from
i1e2-injected animals; however, results were identical with both vMOs. Fish were
∼9 mm standard length. (G) Probability density functions to represent VAT-LD
diameter distributions after manipulation of col5a1. VAT-LD diameters were
modeled using a mixture of two or three normal distributions. The mean (μ) of
each distribution is indicated (μ1, μ2, and μ3). (H) Injection of col5a1 vMO nor-
malizes the hyperproliferation observed in plxnd1 VAT. (I) Injection of col5a1
vMO increases VAT cumulative volume in plxnd1mutants. (J) Injection of col5a1
vMO increases the VAT:SAT ratio in plxnd1 mutants. For F–J, data were
pooled from both col5a1-i1e2 and col5a1-e3i3 vMO-injected animals.














mutant SVCs in sibling ECM abrogated the hyperproliferation
and smaller LD size observed in the mutant experiment, leading
to larger LDs more reminiscent of sibling:sibling cocultures (Fig.
3 E–G). Moreover, combining ECM extract from siblings and
plxnd1 mutants produced intermediate morphologies dependent
on the proportion of wild-type sibling:plxnd1 mutant ECM (SI
Appendix, Fig. S13 B and C), suggesting that the capacity of
plxnd1 mutant ECM to induce proliferation and hyperplastic
morphology is proportional to the amount of plxnd1 mutant
ECM present. Injection of col5a1 vMO before ECM extraction
abrogated the ability of plxnd1 mutant ECM to induce pro-
liferation and hyperplastic morphology in cultured plxnd1 mu-
tant SVCs (SI Appendix, Fig. S13 D and E). These data
demonstrate that plxnd1 mutant ECM is sufficient to induce
hyperproliferation of SVCs and a smaller overall size of LDs.
Lipid Is Preferentially Deposited in SAT of plxnd1 Mutants Fed a
High-Fat Diet. Considering the global obesity epidemic and the in-
fluence of body fat distribution on metabolic dysfunction, we next
examined the effect of a high-fat diet on regional adiposity and
metabolism in plxnd1 mutant zebrafish. We used daily immer-
sion in 5% chicken egg yolk over the course of 2–3 wk as a high-
fat dietary supplement (HFD); this has previously been shown
to induce lipid accumulation and metabolism in zebrafish (29–
32). HFD treatment led to equivalent increases in lipid accu-
mulation in both plxnd1/+ heterozygotes and homozygous
plxnd1 mutants (Fig. 4 A and B and SI Appendix, Fig. S14A). A
substantial increase in total VAT and SAT area (SI Appendix,
Fig. S14 B and C) and VAT and SAT LD size was observed
in heterozygotes (Fig. 4 A, D–G). However, VAT in HFD fed
plxnd1 mutants did not expand (SI Appendix, Fig. S14B), and
VAT-LDs did not substantially increase in size (Fig. 4 A, D–G).
Strikingly, plxnd1 mutants underwent a larger expansion of SAT
compared with heterozygotes (SI Appendix, Fig. S14C), leading to
supersized SAT-LDs (Fig. 4 A, E, and G) and a decreased VAT:
SAT ratio (Fig. 4C). Together, these data show that the absence of
Plxnd1 results in a preferential expansion of SAT in response to
HFD, and thus leads to further exacerbation of altered body
fat distribution.
Plxnd1 Deficiency Protects Zebrafish from High-Fat Diet-Induced
Insulin Resistance. We hypothesized that decreased VAT:SAT
ratio in plxnd1 mutants was associated with improved insulin
sensitivity. HFD-fed wild-type siblings had hyperglycemia (Fig.
5A). Further, after a glucose tolerance test, siblings fed a HFD
failed to normalize blood glucose levels, suggesting a degree
of systemic insulin resistance (Fig. 5B). In contrast, plxnd1
Fig. 3. The extracellular matrix of plxnd1mutant VAT is sufficient to induce
hyperplastic morphology in a Col5a1-dependent manner. (A) 3D renderings
of sibling or plxnd1 mutant VAT stained with LipidTOX (LDs, red) and 5-(4,6-
dichlorotriazinyl) aminofluorescein (collagen, cyan). (B and C) Turbidity
assays reveal a Col5a1-dependent increase in the rate of fibrillogenesis (B)
and a greater ultimate turbidity (C), suggesting increased collagen fibrils
within plxnd1 VAT. (D) Schematic of ECM and SVC 3D coculture experi-
mental design. Briefly, ECM and SVCs were isolated from either sibling or
plxnd1 mutant VAT. The isolated ECM was then used as a 3D substrate for
SVC culture. (E) Maximum-intensity projections of adipogenic clusters after
10 d of 3D culture. SVCs were isolated from either sibling (blue) or plxnd1
(magenta) VAT and used to seed either sibling (blue) or plxnd1 (magenta)
ECM gels. A range in nuclear morphologies was observed in the 3D cultures
that likely represents the heterogeneous cellular nature of the stromal
vascular fraction. (F) Confluency (percentage of field occupied by cells) of 3D
cultures. (G) Mean LD size of 3D cultures. LD sizes were normally distributed.
Fig. 4. VAT fails to expand in homozygous plxnd1 mutants fed a high-fat
diet, leading to disproportionately large increases in SAT. (A) Nile Red-
stained zebrafish after 14 d of normal or high-fat diet. Groups were either
plxnd1 homozygous mutants (plxnd1) or plxnd1 heterozygotes (plxnd1/+).
(Left) Whole-animal body fat distribution, with areas enlarged on the right
denoted by colored boxes. Experimental groups are colorized (plxnd1/+ fed
control diet, black; plxnd1/+ fed high-fat diet, blue; plxnd1 fed control diet,
magenta; plxnd1 fed high-fat diet, orange). Arrows indicate excess lipid
deposition in SAT after feeding of HFD. (B) Total adipose area relative to
standard length revealed greater lipid storage and deposition after HFD
intervention. (C) plxnd1 mutants fed a HFD had a greater VAT:SAT ratio
indicating disproportionate lipid storage in SAT. (D) Probability density
functions of VAT LD sizes. All groups exhibited bimodal LD size distributions.
(E) Probability density functions of SAT LD sizes. All groups exhibited
unimodal LD size distributions. (F) Means of bimodal VAT-LD size dis-
tributions. (G) Means of unimodal SAT-LD size distributions.
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mutants fed a HFD did not exhibit hyperglycemia (Fig. 5A) and
efficiently normalized hyperglycemia after a glucose tolerance
test (Fig. 5B). The insulin receptor substrates 1 and 2 (irs1, irs2)
are negatively regulated in insulin resistance (33–35). However,
in both control and HFD-fed plxnd1 VAT, irs1 and irs2 mRNAs
were increased compared with siblings, supporting augmented
insulin signaling in plxnd1 mutants (Fig. 5C). Together, these
data indicate that high-fat feeding induces a state reminiscent of
insulin resistance in wild-type sibling zebrafish, and Plxnd1 de-
ficiency protects from HFD-induced insulin resistance.
Increased PLXND1 mRNA in Human VAT Is Associated with Type 2
Diabetes. As Plxnd1 deficiency protects zebrafish from HFD-
induced insulin resistance, we hypothesized PLXND1 mRNA
would be positively associated with insulin resistance and type 2
diabetes in humans. Strikingly, analysis of PLXND1 mRNA
levels in VAT and SAT from lean, healthy obese, and type 2
diabetic obese patients revealed that PLXND1 mRNA was spe-
cifically increased in VAT of obese patients with type 2 diabetes
(Fig. 5D), whereas no change was observed in SAT (Fig. 5D) or
AT of healthy obese patients (Fig. 5D), suggesting a role for
VAT PLXND1 in insulin sensitivity. Moreover, in HFD-fed
zebrafish that exhibit features of insulin resistance, VAT-local-
ized plxnd1 mRNA was up-regulated (SI Appendix, Fig. S15D),
suggesting the positive association between VAT plxnd1 mRNA
levels and insulin resistance is conserved to zebrafish.
Discussion
Genome-wide association studies have implicated PLXND1 in
the regulation of body fat distribution and type 2 diabetes (10).
However, a role for PLXND1 in regional adiposity has not been
described, nor has direct evidence of a role in human metabolic
disease been established. Our data establish three key points.
First, Plxnd1 regulates body fat distribution by determining the
growth characteristics of VAT. Second, the effect of Plxnd1 in
VAT is mediated by Col5a1 and the establishment of an ECM
microenvironment that is conducive to hyperplastic growth. Third,
Plxnd1 deficiency protects zebrafish from HFD-induced insulin
resistance and glucose intolerance, in accord with association data
from humans showing that VAT PLXND1mRNA levels correlate
with insulin resistance and type 2 diabetes. Thus, our data suggest
that Plxnd1 promotes VAT hypertrophy and growth and insulin
resistance in both zebrafish and humans, and identifies PLXND1
as a new target for treatment of metabolic disease.
We propose a model whereby Plxnd1 regulates the mechanism
of VAT growth by determining the status of the VAT ECM
microenvironment (Fig. 5E and SI Appendix, Fig. S16). Our data
show that in Plxnd1-deficient VAT, the induction of Col5a1
promotes adipocyte proliferation and differentiation, leading to
hyperplastic VAT morphology and reduced lipid accumulation.
Moreover, our data show that Col5a1 induction in plxnd1
mutants is localized to vascular endothelial cells, suggesting that
blood vessels are the source of altered VAT morphology and
body fat distribution. In normally fed animals, SAT is not sig-
nificantly affected by Plxnd1 deficiency. However, after high-fat
feeding of plxnd1 mutants, VAT fails to expand, and excess lipid
is stored in SAT. Thus, we propose that impaired VAT expansion
in plxnd1 mutants leads to increased, and perhaps compensatory,
lipid storage in SAT. A VAT-specific role for Plxnd1 is supported
by gene expression data from humans that show PLXND1 mRNA
is positively correlated with hypertrophic morphology in VAT,
with no association found between morphology and PLXND1
in SAT.
The relative abundance of VAT and SAT strongly influence
susceptibility to metabolic disease. Previous studies suggest that
impaired SAT expansion leads to increased lipid accumulation in
VAT and subsequent metabolic complications (36–38). As such,
SAT acts as a “lipid buffer” that protects other tissues, including
VAT, from excessive lipid exposure. In a similar manner, our
HFD data suggest that impaired VAT growth in plxnd1 mutants
positively influences lipid deposition in SAT. Intriguingly, the
thiazolidinedione class of peroxisome-proliferator activated re-
ceptor ligands influences body fat distribution and decreases
VAT:SAT ratio (39–41). Interestingly, we observe an increase in
ppargmRNA in both control and HFD-fed plxnd1 VAT, suggesting
pparg induction within VAT may underlie the observed altered
body fat distribution. In accordance, thiazolidinedione treatment
has been shown to solely influence VAT growth in humans (40),
although other studies suggest SAT is also affected (39). An in-
creased proportion of small adipocytes in SAT is correlated with
metabolic disturbance (38, 42). We found plxnd1 mutants had an
increased ratio of small:large LDs in VAT (SI Appendix, Fig. S17);
however, as we observe increased proliferation and differentiation
in plxnd1mutant VAT, we believe this phenotype is likely different
from the impaired differentiation observed in human insulin-
resistant SAT (38).
Type V collagens have not been previously implicated in the
regulation of in vivo AT growth or body fat distribution. Type V
collagens are expressed by preadipocytes (43) and have a stimu-
latory effect on adipocyte hyperplasia (19). Indeed, adipocyte
differentiation is characterized by increased collagen V ac-
cumulation, followed by a decline in collagen V as adipose
maturation proceeds (20). Thus, collagen V is associated with
“hyperplastic” adipose conditions. Our data support a role for
Fig. 5. Mutation of plxnd1 protects zebrafish from high-fat-diet-induced
insulin resistance. (A) Basal blood glucose measurements reveal that wild-
type siblings fed a high-fat (HF) diet are hyperglycemic. (B) Glucose tolerance
tests reveal wild-type siblings fed a high-fat (HF) diet have a decreased ca-
pacity to normalize blood glucose relative to control-fed siblings (P < 0.001).
plxnd1 mutants fed a control diet have an enhanced capacity to normalize
blood glucose relative to control-fed siblings (P < 0.01), whereas plxnd1
mutants fed a HF diet have equivalent capacity to normalize experimentally
induced hyperglycemia to control-fed siblings (P > 0.05). One-factor ANOVA
followed by Tukey’s HSD test (α = 0.05) was used to determine statistical
significance at 120 min. (C) qRT-PCR analysis of markers of insulin signaling
and metabolism in zebrafish VAT. (D) PLXND1 mRNA is significantly up-
regulated in VAT, but not SAT, of obese patients with type 2 diabetes.
(E) Schematic illustrating the current working model of Plxnd1-mediated
regulation of VAT morphology.














Col5a1 in hyperplastic AT morphology. We speculate that
Col5a1 may be selectively induced in situations in which hyper-
plastic growth is needed, such as insulin-resistant AT. Collagen in
obese AT correlates with insulin resistance and metabolic disease
and is thus often considered pathological (44). Our data suggest
that increased Col5a1 is metabolically beneficial. Intriguingly, AT
of healthy children contains increased collagen accumulation that
is correlated with decreased adipocyte size and body mass index
(45), suggesting AT collagen can be beneficial to AT growth and
expansion in certain human contexts.
Methods
Human Experiments.All human studies were approved by the local committee
on ethics at Karolinska Institutet. Informed consent was obtained from all par-
ticipants. Detailed methods are included in SI Appendix.
Zebrafish and Mouse Experiments. All zebrafish and mouse experiments
conformed to the Public Health Service Policy on Humane Care and Use of
Laboratory Animals, using protocols approved by the Institutional Animal
Care and Use Committee of the University of North Carolina at Chapel Hill,
Duke University, and the University of Pennsylvania. Detailed zebrafish
methods are included in SI Appendix.
Statistics. Statistical analyses were conducted in GraphPad Prism 5.04
(GraphPad Software) or JMP Pro-11.0.0 (SAS Institute). For pairwise anal-
yses, independent Student’s t test was used to compare means assuming
unequal variance: ns = not significant (P > 0.05); *P < 0.05; **P < 0.01;
***P < 0.001. One-way ANOVA followed by Tukey’s HSD test was used
when comparing three or more means. Groups with the same letters
are not significantly different (α = 0.05). Probability density functions
were used to describe the likelihood of LD sizes. Bars are mean ± SEM
unless stated.
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